FLYY INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Spirit Aviation Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

(PinkSheets:FLYYQ), NEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) — Attorney Advertising — Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Spirit Aviation Holdings, Inc. (“Spirit” or “the Company”) (OTCMKTS: FLYYQ) and certain of its officers. Class Definition This lawsuit seeks to recover […]

Arctic Wolf Invests to Advance Aurora Endpoint Security with AI-Powered Ransomware Prevention and Rollback Capabilities

EDEN PRAIRIE, Minn., Nov. 04, 2025 (GLOBE NEWSWIRE) — Arctic Wolf(R), a global leader in security operations, today announced plans to enhance Aurora(TM) Endpoint Security with upcoming AI-powered ransomware prevention and rollback capabilities. Through the acquisition of UpSight Security, Arctic Wolf will accelerate the development and future delivery of these features, expanding its ability to

FOX Unveils Live Valve Aftermarket Kits: the most advanced semi active suspension, now offered through aftermarket sales channels

(NASDAQ:FOXF), DULUTH, Ga., Nov. 04, 2025 (GLOBE NEWSWIRE) — FOX continues to push the potential of suspension technology with the introduction of Live Valve as an aftermarket upgrade for trucks and Jeeps. Live Valve is the most advanced semi active suspension system available for trucks and Jeeps. It senses terrain and driver inputs hundreds of times

Omada Health to Present Real-World Evidence at ObesityWeek 2025 Demonstrating Enhanced Outcomes for Current and Former GLP-1 Users

(NASDAQ:OMDA), SAN FRANCISCO, Nov. 04, 2025 (GLOBE NEWSWIRE) — Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, announced it will present two posters at ObesityWeek 2025 highlighting the potential impact of Omada's behavior change program on members currently or previously on GLP-1 medications for weight loss. Together, these analyses suggest that engagement with Omada

Aardvark Therapeutics Presents Data Supporting its Metabolic Obesity Pipeline Programs at ObesityWeek 2025

(NASDAQ:AARD), New preclinical results demonstrate the potential of ARD-201 in enhanced glucose control, along with preservation of lean mass, underscoring its opportunity in addressing key challenges in today's obesity treatment landscape Preclinical and clinical data demonstrates the potential of ARD-201 to attenuate weight gain, promote weight loss and help maintain weight after the discontinuation of

Chainlink and Validation Cloud Collaborate to Power Institutional DeFi With Cross-Chain Interoperability and AI

NEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) — Today, Chainlink and Validation Cloud announced a collaboration between Mavrik, Validation Cloud's domain-specific AI engine, and Chainlink's Cross-Chain Interoperability Protocol (CCIP). The collaboration seeks to connect artificial intelligence and cross-chain connectivity to redefine how institutions understand, navigate, and move digital assets across networks. The collaboration targets the

Questex Strengthens its Leadership Position in the Booming $88.2 Billion Life Sciences Industry, Acquires The Conference Forum and Versalinx Global Events

NEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) — Questex, a leading authority in the healthcare and life sciences sector, today announces the acquisitions of The Conference Forum and Versalinx Global Events. The life sciences industry is booming with $88.2 billion in sales (2024) and is expected to grow to $269.56 billion by 2034, at a

Rivus Pharmaceuticals Presents Preclinical Data for Controlled Metabolic Accelerator (CMA) Pipeline Showing Fat-Selective, Muscle-Preserving Weight Loss in Obesity at ObesityWeek(R)

CHARLOTTESVILLE, Va. and SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) — Rivus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to treating obesity and associated cardiometabolic diseases, today announced that a poster of the first data from the company's preclinical pipeline of oral Controlled Metabolic Accelerators (CMAs) will be presented at ObesityWeek(R) organized by

SNPS INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Synopsys, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

(NASDAQ:SNPS), NEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) — Attorney Advertising–Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Synopsys, Inc. (“Synopsys” or “the Company”) (NASDAQ: SNPS) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for

Scroll to Top